Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Immune checkpoint inhibitors have significantly improved overall survival with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients. However, not all patients are sensitive to immune checkpoint blockade and, in some cases, programmed death 1 (PD-1)...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-04-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/1758835918762094 |
| id |
doaj-8b2f039b0195440fa399e60bb50323eb |
|---|---|
| record_format |
Article |
| spelling |
doaj-8b2f039b0195440fa399e60bb50323eb2020-11-25T03:49:57ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592018-04-011010.1177/1758835918762094Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?Chiara LazzariNiki KarachaliouAlessandra BulottaMariagrazia ViganóAurora MirabileElena BrioschiMariacarmela SantarpiaLuca GianniRafael RosellVanesa GregorcImmune checkpoint inhibitors have significantly improved overall survival with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients. However, not all patients are sensitive to immune checkpoint blockade and, in some cases, programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors accelerate tumor progression. Several combination strategies are under evaluation, including the concomitant or sequential evaluation of chemotherapy or radiotherapy with immunotherapy. The current review provides an overview on the molecular rationale for the investigation of combinatorial approaches with chemotherapy or radiotherapy. Moreover, the results of completed clinical studies will be reported.https://doi.org/10.1177/1758835918762094 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Chiara Lazzari Niki Karachaliou Alessandra Bulotta Mariagrazia Viganó Aurora Mirabile Elena Brioschi Mariacarmela Santarpia Luca Gianni Rafael Rosell Vanesa Gregorc |
| spellingShingle |
Chiara Lazzari Niki Karachaliou Alessandra Bulotta Mariagrazia Viganó Aurora Mirabile Elena Brioschi Mariacarmela Santarpia Luca Gianni Rafael Rosell Vanesa Gregorc Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? Therapeutic Advances in Medical Oncology |
| author_facet |
Chiara Lazzari Niki Karachaliou Alessandra Bulotta Mariagrazia Viganó Aurora Mirabile Elena Brioschi Mariacarmela Santarpia Luca Gianni Rafael Rosell Vanesa Gregorc |
| author_sort |
Chiara Lazzari |
| title |
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? |
| title_short |
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? |
| title_full |
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? |
| title_fullStr |
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? |
| title_full_unstemmed |
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? |
| title_sort |
combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? |
| publisher |
SAGE Publishing |
| series |
Therapeutic Advances in Medical Oncology |
| issn |
1758-8359 |
| publishDate |
2018-04-01 |
| description |
Immune checkpoint inhibitors have significantly improved overall survival with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients. However, not all patients are sensitive to immune checkpoint blockade and, in some cases, programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors accelerate tumor progression. Several combination strategies are under evaluation, including the concomitant or sequential evaluation of chemotherapy or radiotherapy with immunotherapy. The current review provides an overview on the molecular rationale for the investigation of combinatorial approaches with chemotherapy or radiotherapy. Moreover, the results of completed clinical studies will be reported. |
| url |
https://doi.org/10.1177/1758835918762094 |
| work_keys_str_mv |
AT chiaralazzari combinationofimmunotherapywithchemotherapyandradiotherapyinlungcanceristhisthebeginningoftheendforcancer AT nikikarachaliou combinationofimmunotherapywithchemotherapyandradiotherapyinlungcanceristhisthebeginningoftheendforcancer AT alessandrabulotta combinationofimmunotherapywithchemotherapyandradiotherapyinlungcanceristhisthebeginningoftheendforcancer AT mariagraziavigano combinationofimmunotherapywithchemotherapyandradiotherapyinlungcanceristhisthebeginningoftheendforcancer AT auroramirabile combinationofimmunotherapywithchemotherapyandradiotherapyinlungcanceristhisthebeginningoftheendforcancer AT elenabrioschi combinationofimmunotherapywithchemotherapyandradiotherapyinlungcanceristhisthebeginningoftheendforcancer AT mariacarmelasantarpia combinationofimmunotherapywithchemotherapyandradiotherapyinlungcanceristhisthebeginningoftheendforcancer AT lucagianni combinationofimmunotherapywithchemotherapyandradiotherapyinlungcanceristhisthebeginningoftheendforcancer AT rafaelrosell combinationofimmunotherapywithchemotherapyandradiotherapyinlungcanceristhisthebeginningoftheendforcancer AT vanesagregorc combinationofimmunotherapywithchemotherapyandradiotherapyinlungcanceristhisthebeginningoftheendforcancer |
| _version_ |
1724492967651049472 |